Business Context and Reporting Period
This Form 10-Q is a quarterly report for PerkinElmer, Inc. (Note: The input metadata lists "REVVITY, INC.", but the filing text explicitly identifies the registrant as PerkinElmer, Inc.). The report covers the quarterly period ended July 1, 2007, and the six-month period ended July 1, 2007. PerkinElmer operates in two primary segments: Life and Analytical Sciences (drug discovery, genetic screening, environmental analysis) and Optoelectronics (digital imaging, sensors, specialty lighting).
Key Financial Metrics
| Metric | Three Months Ended July 1, 2007 | Six Months Ended July 1, 2007 |
|---|---|---|
| Sales | $437.3 million | $840.2 million |
| Operating Income | $48.1 million | $71.2 million |
| Net Income | $33.7 million | $48.4 million |
| Diluted EPS | $0.28 | $0.40 |
| Gross Margin | 39.8% | 39.6% |
| Cash and Cash Equivalents | $150.0 million (as of July 1, 2007) | N/A |
| Long-Term Debt | $234.5 million (as of July 1, 2007) | N/A |
| Operating Cash Flow | N/A | $87.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 16% year-over-year for the quarter and 15% for the six-month period. Growth was driven by acquisitions ($15.3M impact in Q2; $27.1M in YTD) and favorable foreign exchange rates ($10.7M impact in Q2; $23.4M in YTD).
- Profitability: Operating income rose 35% in the quarter and 10% YTD. However, gross margins compressed slightly (40 basis points) due to increased amortization from acquisitions, inventory revaluation, and start-up costs for new laboratory service contracts.
- Unusual Items:
- Insurance Gain: A one-time gain of $15.3 million was recorded in Q2 from the settlement of an insurance claim related to a 2005 fire at a Boston facility.
- Restructuring/Lease Charges: Net charges of $4.5 million in Q2 included a $4.5 million charge related to a lease guarantee for a divested business where the buyer defaulted.
- IPR&D Charges: A $1.5 million charge was recorded for in-process research and development related to the Evotec and Euroscreen acquisitions.
- Segment Performance:
- Life and Analytical Sciences: Sales up 17% (Q2) and 16% (YTD); Operating income up 76% (Q2) and 21% (YTD), significantly boosted by the insurance gain.
- Optoelectronics: Sales up 13% (Q2) and 12% (YTD); Operating income declined 25% (Q2) and 3% (YTD) due to lease charges and one-time flash module contract costs.
Guidance, Outlook, and Risks
- Leadership Succession: The Board approved a succession plan. Robert F. Friel was elected President and COO (effective Aug 1, 2007), with an expected transition to CEO in February 2008. Current CEO Mr. Summe will become Executive Chairman.
- Acquisitions: The company completed several acquisitions in 2007 (Evotec, Euroscreen, Improvision, PKI India) to expand capabilities in high-content screening and cellular imaging. Management expects these to be accretive but notes integration risks.
- Capital Allocation: The company repurchased approximately 6.0 million shares for $147.1 million in the first six months of 2007. A $350 million senior unsecured revolving credit facility is in place, with $234.4 million outstanding as of July 1, 2007.
- Risks and Contingencies:
- Legal Proceedings: Ongoing patent litigation with Enzo Biochem and Amersham Biosciences. The company believes it has meritorious defenses but cannot estimate potential losses.
- Environmental: Accrued $4.0 million for environmental remediation; potential for additional liability exists but is not expected to be material.
- Market Risk: Exposure to foreign currency fluctuations (approx. 62% of business outside the U.S.) and interest rate changes on variable-rate debt.
Investor Verification Checklist
- Insurance Settlement: Verify the sustainability of earnings excluding the $15.3 million one-time insurance gain.
- Lease Guarantee Liability: Assess the impact of the $4.5 million charge related to the defaulted lease guarantee and potential future exposure.
- Acquisition Integration: Monitor the integration progress and financial contribution of recent acquisitions (Evotec, Euroscreen, Improvision) to ensure they meet growth targets.
- Legal Exposure: Track the status of the Enzo and Amersham patent lawsuits for potential material adverse impacts.
- Debt Covenants: Confirm continued compliance with financial covenants (interest coverage and debt-to-EBITDA) under the $350 million credit facility.